Clinical Scorecard: Unexpected Role of Fc-Mediated Inhibitory Antibodies in the Protection Offered by Vaccines for HIV and SARS-CoV-2
At a Glance
Category
Detail
Condition
HIV and SARS-CoV-2 infections
Key Mechanisms
Neutralizing antibodies (NAbs) and Fc-mediated inhibitory antibody functions contribute to vaccine-induced protection; Fc-mediated inhibition may broaden protection against viral variants
Target Population
Individuals at risk of or infected with HIV or SARS-CoV-2
Care Setting
Preventive vaccination and infectious disease management settings
Key Highlights
Neutralizing antibodies are critical for vaccine protection but may be insufficient alone, especially for HIV due to viral mutation and epitope masking.
Fc-mediated inhibitory antibodies, including nonneutralizing Abs, may contribute to immune defense by countering viral escape mutations and broadening protection.
Current knowledge gaps exist regarding the measurement and physiological relevance of Fc-mediated inhibitory functions in vivo for HIV and SARS-CoV-2 vaccines.
Guideline-Based Recommendations
Diagnosis
Use enzyme-linked immunosorbent assay (ELISA) to detect pathogen-specific antibodies as surrogates for vaccine efficacy.
Assess neutralizing antibody activity in vitro to evaluate functional inhibitory capacity.
Management
Develop vaccines that induce broadly neutralizing antibodies (bNAbs) targeting conserved epitopes for HIV to achieve sterilizing immunity.
Employ prime–boost vaccination strategies with novel platforms (antigens, vectors, DNA, mRNA) to enhance antibody maturation and functional activity.
For SARS-CoV-2, utilize mRNA vaccines to induce high levels of neutralizing antibodies against homologous strains, with booster doses to maintain protection.
Monitoring & Follow-up
Monitor antibody levels and neutralizing activity post-vaccination to assess durability of protection.
Investigate Fc-mediated antibody functions as potential correlates of residual protection, especially against emerging viral variants.
Risks
High mutation rates and glycosylation of HIV envelope proteins can lead to immune escape and reduced vaccine efficacy.
Emergence of SARS-CoV-2 variants of concern (VOC) may reduce neutralizing antibody effectiveness, necessitating ongoing vaccine adaptation.
Patient & Prescribing Data
Individuals receiving vaccines for HIV or SARS-CoV-2
Vaccines inducing neutralizing antibodies provide protection, but Fc-mediated inhibitory antibodies may play a crucial complementary role, especially against viral variants and in maintaining residual protection post-vaccination.
Clinical Best Practices
Focus vaccine development on inducing broadly neutralizing antibodies targeting conserved viral epitopes.
Incorporate assessment of Fc-mediated antibody functions in vaccine evaluation to better understand protective mechanisms.
Use prime–boost vaccination regimens with diverse platforms to enhance antibody maturation and functional breadth.
Maintain booster vaccination schedules for SARS-CoV-2 to sustain neutralizing antibody levels and protection against variants.
